Showing results (241-250 of 1,689) with videos related to
Sort By:
Pageof 169
Annals of Surgical Oncology|July 11, 2021
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic TherapyLeisha C Elmore, Henry M Kuerer, Carlos H Barcenas, et al.Cancer|April 30, 2008
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapyJacqueline S Jeruss, Lisa A Newman, Gregory D Ayers, et al.Journal of Immunotherapy and Precision Oncology|January 16, 2025
Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B TrialMohamed A Gouda, Abdulrazzak Zarifa, Yali Yang, et al.Cancer|May 7, 2008
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?Min Yi, Funda Meric-Bernstam, Merrick I Ross, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experienceBanu Arun, Soley Bayraktar, Diane D Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
cMET and phospho-cMET protein levels in breast cancers and survival outcomesKanwal P Raghav, Wenting Wang, Shuying Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancerSao Jiralerspong, Shana L Palla, Sharon H Giordano, et al.Cancer|May 25, 2005
Improving local control with breast-conserving therapy: a 27-year single-institution experienceNeslihan Cabioglu, Kelly K Hunt, Thomas A Buchholz, et al.Cancer|October 13, 2007
Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomyJudy C Boughey, Janice N Cormier, Yan Xing, et al.JCO Precision Oncology|October 31, 2022
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR StudyRanju Gupta, Funda Meric-Bernstam, Michael Rothe, et al.Pageof 169